Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-18T12:50:10.473Z Has data issue: false hasContentIssue false
  • English
  • Français

Human immunodeficiency disease in new diagnoses of head and neck squamous cell cancer: are we testing?

Published online by Cambridge University Press:  11 November 2019

K J McNamara ,
C Fernandez ,
T F C Saunders  and
F Ahsan
K J McNamara*
Affiliation:
Department of Otolaryngology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK
C Fernandez
Affiliation:
Department of Infectious Diseases, Royal Liverpool Hospital, UK
T F C Saunders
Affiliation:
Department of Otolaryngology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK
F Ahsan
Affiliation:
Department of Otolaryngology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK
*
Author for correspondence: Miss Katherine McNamara, Department of Otolaryngology, Shrewsbury and Telford Hospital NHS Trust, Mytton Oak Rd, ShrewsburySY3 8XQ, UK E-mail: kjmcnamara@doctors.org.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Human immunodeficiency virus infected patients have a three-fold increased risk of head and neck squamous cell carcinoma. The British HIV Association recommends human immunodeficiency virus testing in all new diagnoses of head and neck squamous cell carcinoma.

Objectives

This observational study aimed to examine the current routine practice of human immunodeficiency virus testing in patients with newly diagnosed head and neck squamous cell carcinoma, and to address the importance of this test in promoting the early diagnosis and treatment of human immunodeficiency virus.

Methods

All head and neck cancer multidisciplinary teams in England were questioned on their protocol for human immunodeficiency virus testing in new diagnoses of head and neck squamous cell carcinoma.

Results

Only 1 out of 30 hospitals leading head and neck multidisciplinary teams (3.3 per cent) routinely offered human immunodeficiency virus testing in this high-risk patient group.

Conclusion

This observational study highlights that head and neck specialists are not aware of, and are consequently not complying with, routine human immunodeficiency virus testing as recommended by the British HIV Association guidelines.

Keywords

HIVSquamous Cell CarcinomaHead And Neck Cancer
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 133 , Issue 12 , December 2019 , pp. 1038 - 1040
Copyright
Copyright © JLO (1984) Limited, 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Miss K McNamara takes responsibility for the integrity of the content of the paper

References

1UK National Guidelines for HIV Testing. In: http://www.thehealthwell.info/node/553652 [7 September 2019]Google Scholar
2Bower, M, Palfreeman, A, Alfa-Wali, M, Bunker, C, Burns, F, Churchill, D et al. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med 2014;15(suppl 2):1–92Google ScholarPubMed
3Sullivan, AK, Raben, D, Reekie, J, Rayment, M, Mocroft, A, Esser, S et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One 2013;2013:e52845CrossRefGoogle Scholar
4Engsig, FN, Gerstoft, J, Kronborg, G, Larsen, CS, Pedersen, G, Pedersen, C et al. Head and neck cancer in HIV patients and their parents: a Danish cohort study. Clin Epidemiol 2011;3:217–27CrossRefGoogle ScholarPubMed
5National Peer Review Programme. National Peer Review Report. Head and Neck Cancer Services Report 2012/2013. In: https://www.yumpu.com/en/document/read/37930934/national-peer-review-report-head-and-neck-cancer-cquins [7 September 2019]Google Scholar
6Public Health England. Towards Elimination of HIV Transmission, AIDS and HIV-related Deaths in the UK. London: Public Health England, 2017Google Scholar
7Lord, E, Stockdale, AJ, Malek, R, Rae, C, Sperle, I, Raben, D et al. Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. HIV Med 2017;18:300–4CrossRefGoogle ScholarPubMed
8Public Health England. HIV Testing in England: 2017 Report. London: Public Health England, 2017Google Scholar
9Zur Hausen, H.Viruses in human cancer. Science 1991;254:1167–73CrossRefGoogle Scholar
10McLemore, MS, Haigentz, M Jr, Smith, RV, Nuovo, GJ, Alos, L, Cardesa, A et al. Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 2010;4:97–105CrossRefGoogle ScholarPubMed
11Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic. Geneva: UNAIDS, 2014Google Scholar
12Mocroft, A, Lundgren, JD, Sabin, ML, Monforte, AD, Brockmeyer, N, Casabona, J et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013;10:e1001510CrossRefGoogle Scholar
13Lundgren, JD, Babiker, AG, Gordin, F, Emery, S, Grund, B, Sharma, S et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795–807Google ScholarPubMed
14D'Souza, G, Carey, TE, William, WN, Nguyen, ML, Ko, EC, Riddell, J et al. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 2014;65:603–10CrossRefGoogle ScholarPubMed
15Purgina, B, Pantanowitz, L, Seethala, RR.A review of carcinomas arising in the head and neck region in HIV-positive patients. Patholog Res Int 2011;2011:469150Google ScholarPubMed
16Singh, B, Sabin, S, Rofim, O, Shaha, A, Har-El, G, Lucente, F.Alterations in head and neck cancer occurring in HIV-infected patients—results of a pilot, longitudinal, prospective study. Acta Oncol 1999;38:1047–50CrossRefGoogle ScholarPubMed